KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Cash from Investing Activities: 2016-2024

Historic Cash from Investing Activities for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Dec 2024 value amounting to -$63.0 million.

  • Amneal Pharmaceuticals' Cash from Investing Activities fell 8.46% to -$22.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$82.9 million, marking a year-over-year decrease of 5.39%. This contributed to the annual value of -$63.0 million for FY2024, which is 8.95% up from last year.
  • Per Amneal Pharmaceuticals' latest filing, its Cash from Investing Activities stood at -$63.0 million for FY2024, which was up 8.95% from -$69.2 million recorded in FY2023.
  • In the past 5 years, Amneal Pharmaceuticals' Cash from Investing Activities registered a high of -$63.0 million during FY2024, and its lowest value of -$317.5 million during FY2020.
  • In the last 3 years, Amneal Pharmaceuticals' Cash from Investing Activities had a median value of -$69.2 million in 2023 and averaged -$102.2 million.
  • As far as peak fluctuations go, Amneal Pharmaceuticals' Cash from Investing Activities slumped by 1,521.79% in 2020, and later soared by 60.31% in 2023.
  • Yearly analysis of 5 years shows Amneal Pharmaceuticals' Cash from Investing Activities stood at -$317.5 million in 2020, then skyrocketed by 38.85% to -$194.2 million in 2021, then climbed by 10.23% to -$174.3 million in 2022, then skyrocketed by 60.31% to -$69.2 million in 2023, then rose by 8.95% to -$63.0 million in 2024.